Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial.
about
Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Irbesartan treatment does not ...... anced glycation end products N
@nl
Irbesartan treatment does not ...... A randomized controlled trial.
@en
type
label
Irbesartan treatment does not ...... anced glycation end products N
@nl
Irbesartan treatment does not ...... A randomized controlled trial.
@en
prefLabel
Irbesartan treatment does not ...... anced glycation end products N
@nl
Irbesartan treatment does not ...... A randomized controlled trial.
@en
P2093
P50
P356
P1476
Irbesartan treatment does not ...... A randomized controlled trial.
@en
P2093
Coen D Stehouwer
Hans-Henrik Parving
Lian Engelen
Peter Hovind
Tom Teerlink
P304
P356
10.1093/NDT/GFR102
P407
P577
2011-03-08T00:00:00Z